Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer
The nomogram developed herein is a reliable tool for predicting eligibility for SL chemotherapy among PC patients, thereby facilitating informed treatment decisions.
Authors
- Hiroshi Shimizu (ORCID: https://orcid.org/0000-0002-4869-502X)
- Mitsuru Sugimoto (ORCID: https://orcid.org/0000-0002-4223-613X)
- Hiromasa Ohira (ORCID: https://orcid.org/0000-0003-4331-0634)
- Naoki Konno (ORCID: https://orcid.org/0000-0001-9830-4317)
- Kentaro Sato (ORCID: https://orcid.org/0000-0001-6706-2175)
- Yuichi Waragai
- Hiroyuki Asama (ORCID: https://orcid.org/0000-0002-0102-0404)
- Ko Watanabe (ORCID: https://orcid.org/0000-0003-0252-1785)
- Hiroki Irie (ORCID: https://orcid.org/0000-0002-4805-6244)
- Rei Suzuki (ORCID: https://orcid.org/0000-0002-5093-6726)
- Hiromichi Imaizumi
- Rei Ohira
Institutions
- Fukushima Medical University (JP)
- Tokushima Red Cross Hospital (JP)
- Seirei Hamamatsu General Hospital (JP)
- Fukushima Medical University Hospital (JP)
- Soma Central Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-09-26
- DOI
- https://doi.org/10.21873/anticanres.17798
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00